Comparative in vivo and in vitro regional selectivity of central omega (benzodiazepine) site ligands in inhibiting [3H]flumazenil binding in the rat central nervous system.
The DOI matches its Crossref record.
Abstract
The in vivo selectivity for central omega (benzodiazepine) modulatory site subtypes of ligands from several chemical classes has been evaluated by measuring the displacement of the in vivo binding of [3H]flumazenil to several rat central nervous system structures differentially enriched in omega 1 and omega 2 sites. This labeling was prevented in a dose-related manner by the i.p. administration, 30 min before the radioligand, of several benzodiazepine derivatives, the cyclopyrrolone derivatives suriclone and zopiclone, the triazolopyridazine derivative CL 218,872 and the imidazopyridine derivative zolpidem. Most of the benzodiazepine derivatives studied displayed in vivo some selectivity for omega 2-enriched structures. In contrast, oxoquazepam and CL 218,872 were 2- to 3-fold more potent at preventing [3H]flumazenil binding in omega 1-enriched (cerebellum) than in omega 2-enriched structures. Maximal inhibitions by zolpidem of in vivo [3H]flumazenil binding [cerebellum (100%) > cerebral cortex (79%) > or = striatum (74%) > hippocampus (52%) > spinal cord (37%)] were related to the relative omega 1/omega 2 distribution ratio in each structure. These differences did not result from an uneven distribution of this compound in the central nervous system. Quantitative autoradiographic studies performed on 30 central nervous system regions showed a strong correlation between the in vitro and in vivo regional selectivity of zolpidem. For all the drugs studied there was a significant global correlation between their potency at inhibiting [3H]flumazenil binding in vitro and in vivo either in the cerebellum (P < .001) or in the spinal cord (P < .01) and between the in vitro and in vivo cerebellum/spinal cord selectivity. The differential in vivo selectivity of zolpidem may account for the reported hypnoselective profile of this imidazopyridine in the rodent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fritschy, J., & Mohler, H. (1995) · Journal of Comparative Neurology · doi:10.1002/cne.903590111 · Cited by 1,244
Christian, E. P., Snyder, D. H., Song, W., Gurley, D. A., Smolka, J., Maier, D. L., Ding, M., Gharahdaghi, F., Liu, X. F., Chopra, M., et al. (2015) · Journal of Neurophysiology · doi:10.1152/jn.00539.2013 · Cited by 68
The Pharmacology and Mechanism of Action of Zolpidem
Sanger, D. J., & Depoortere, H. (1998) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1998.tb00074.x · Cited by 58
“The binding of zolpidem to BZ(ω) receptors in different regions of the CNS has also been investigated in vivo in rodents sacrificed after systemic administration of drug and labeled ligand (10,11) and in baboons and humans using positron emission tomography (1,76).”
Huang, M. P., Radadia, K., Macone, B. W., Auerbach, S. H., & Datta, S. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.02.018 · Cited by 39
“zolpidem has a high affinty for GABA-A receptors containing the 1 subunit, low affinity or 2- and 3-containing receptors, and no significant affinity or 5-containing receptors [2,38,74,108].”
BackgroundHigashima, M., Kinoshita, H., & Koshino, Y. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00178-5 · Cited by 25
Metadata
- Authors
- Benavides, J., Peny, B., Durand, A., Arbilla, S., & Scatton, B.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 1992-11
- Volume
- 263
- Issue
- 2
- Pages
- 884-896
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2256029624
- Cited by
- 50
- References
- 0
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative in vivo and in vitro regional selectivity of central omega (benzodiazepine) site ligands in inhibiting [3H]flumazenil binding in the rat central nervous system. https://app.cochat.ai/papers/10.1016/s0022-3565(25)10428-x
- The paper
- Benavides, J., Peny, B., Durand, A., Arbilla, S., & Scatton, B. (1992). Comparative in vivo and in vitro regional selectivity of central omega (benzodiazepine) site ligands in inhibiting [3H]flumazenil binding in the rat central nervous system. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/s0022-3565(25)10428-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.